Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ornskov OK With Cinryze 'Cannibalization' As Shire Buys Dyax (And Keeps Baxalta Guessing)

This article was originally published in Scrip

Executive Summary

Shire PLC is to acquire Dyax Corp. for $37.30 in cash per Dyax share, valuing the US biotech at around $5.9bn upfront. Dyax's promising hereditary angioedema (HAE) treatment DX-2930 could generate annual global sales "of up to $2.0bn" if approved for the prevention of type 1 and type 2 HAE, according to Shire. It is likely some of this revenue would come from "cannibalizing" Shire's current successful HAE treatment Cinryze (C1 esterase inhibitor [human]), but this doesn't concern CEO Flemming Ornskov.


Related Content

Shire CEO Says Lanadelumab Results Vindicate Dyax Buy, M&A Strategy
Running The Drug Catalyst Gauntlet: What To Look For In Q2 2017
Shire's Wellhoefer On Genetic Disease R&D And Expanding Access To Medicines
Shire’s Sales, R&D Heads Shed Light On The Post-Baxalta Road Ahead
Shire's Ornskov: The Modest Pediatrician With Fierce Corporate Ambition
Shire Outlines Baxalta Integration Strategy


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts